Targeting KCTD1 As a Potential Novel Therapy Ameliorates Hepatocellular Carcinoma Progression Via the HIF-1α/VEGF Pathway
Xinyu Zhu,Zhiwei Li,Li Chen,Limin Li,Mi Ouyang,Hao Zhou,Kai Xiao,Ling Lin,Paul K. Chu,Chang Zhou,Chengfeng Xun,Liu Yang,Wenhuan Huang,Xiaofeng Ding
DOI: https://doi.org/10.2139/ssrn.4047141
2022-01-01
SSRN Electronic Journal
Abstract:Potassium channel tetramerization domain-containing 1 (KCTD1) plays a critical role in transcriptional regulation and adipogenesis, but the significance of KCTD1 in hepatocellular cancer (HCC) has not been reported. In this study, KCTD1 expression is increased in human HCC tissues and closely associated with advanced tumor stages. KCTD1 overexpression enhances HCC growth, migration, and invasion both in vitro and in vivo , while KCTD1 knockdown reverses these effects. Mechanistically, KCTD1 interacts with hypoxia-inducible factor 1 alpha (HIF-1α), enhances HIF-1α protein stability with the inhibited prolyl-hydroxylases (PHD)/Von Hippel-Lindau (VHL) pathway, consequently activating the Vascular Endothelial Growth Factor (VEGF)/VEGFR2 pathway in HCC cells. Sorafenib and KCTD1 knockdown synergistically inhibit intrahepatic tumor growth. miR-129-5p downregulates KCTD1 expression by binding with KCTD1 3′ UTR. Finally, exosomes derived from miR-129-5p-overexpressing HCC cells combine with sorafenib to decrease HCC tumor size. These results suggest that KCTD1 expression protects HIF-1α from degradation and activates the VEGF signaling cascade to enhance HCC progression. Therefore, KCTD1 may serve as a novel target of HCC and pave the way for an efficient combined therapy for advanced human HCC.Funding Information: This work was supported by the National Natural Science Foundation of China (No. 81872256), Key grant of research and development in Hunan Province (No. 2020DK2002), Natural Science Foundation in Hunan Province (NO.2021JJ30453), Key project of Hunan Provincial Education Department (No.19A310), Cooperative Innovation Center of Engineering and New Products for Developmental Biology of Hunan Province (No.20134486), as well as City University of Hong Kong Strategic Research Grant (No. 7005264).Declaration of Interests: These authors declare no competing financial interests.Ethics Approval Statement: This study was approved by the ethical principles and guidelines for Experiments on Animals and HCC tissues of Hunan Normal University (2018-035). Informed consent was gotten from all participants.